ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
FDA red and green lights: August 2025
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
